CG0070 + Nivolumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle-Invasive Bladder Carcinoma
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Trial Timeline
Oct 26, 2020 → Jul 25, 2024
NCT ID
NCT04610671About CG0070 + Nivolumab
CG0070 + Nivolumab is a phase 1 stage product being developed by CG Oncology for Muscle-Invasive Bladder Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04610671. Target conditions include Muscle-Invasive Bladder Carcinoma, Bladder Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04610671 | Phase 1 | Completed |
Competing Products
12 competing products in Muscle-Invasive Bladder Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab (Imfinzi) + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Gemcitabine | Merck | Phase 2 | 52 |
| Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance | Merck | Phase 2 | 52 |
| Autogene Cevumeran + Nivolumab + Saline | Roche | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Nivolumab + Nab-paclitaxel + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| REOLYSIN® + Gemcitabine + Cisplatin | Oncolytics Biotech | Phase 1 | 25 |